Cullinan Therapeutics (CGEM) Competitors $7.89 +0.28 (+3.68%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$7.88 0.00 (-0.06%) As of 04/17/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. ARQT, RXRX, DNLI, HRMY, BEAM, GLPG, CNTA, AGIO, KNSA, and ANIPShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Beam Therapeutics (BEAM), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), Kiniksa Pharmaceuticals (KNSA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Arcutis Biotherapeutics Recursion Pharmaceuticals Denali Therapeutics Harmony Biosciences Beam Therapeutics Galapagos Centessa Pharmaceuticals Agios Pharmaceuticals Kiniksa Pharmaceuticals ANI Pharmaceuticals Arcutis Biotherapeutics (NASDAQ:ARQT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings. Which has higher earnings & valuation, ARQT or CGEM? Cullinan Therapeutics has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M7.85-$262.14M-$1.16-11.22Cullinan TherapeuticsN/AN/A-$153.16M-$3.03-2.60 Is ARQT or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Cullinan Therapeutics' return on equity of -26.54% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Cullinan Therapeutics N/A -26.54%-25.32% Do analysts prefer ARQT or CGEM? Arcutis Biotherapeutics currently has a consensus price target of $18.80, suggesting a potential upside of 44.50%. Cullinan Therapeutics has a consensus price target of $34.80, suggesting a potential upside of 341.06%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ARQT or CGEM? Arcutis Biotherapeutics received 26 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.64% of users gave Cullinan Therapeutics an outperform vote while only 67.92% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes7267.92% Underperform Votes3432.08% Cullinan TherapeuticsOutperform Votes4683.64% Underperform Votes916.36% Do insiders and institutionals believe in ARQT or CGEM? 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer ARQT or CGEM? In the previous week, Cullinan Therapeutics had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for Cullinan Therapeutics and 5 mentions for Arcutis Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.75 beat Arcutis Biotherapeutics' score of 0.69 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ARQT or CGEM? Arcutis Biotherapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. SummaryCullinan Therapeutics beats Arcutis Biotherapeutics on 12 of the 17 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$461.67M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-2.7830.4821.8617.80Price / SalesN/A441.91380.5497.75Price / CashN/A168.6838.2634.64Price / Book0.743.466.453.98Net Income-$153.16M-$72.06M$3.22B$247.81M7 Day Performance2.33%2.54%2.85%1.80%1 Month Performance-11.65%-15.71%-8.67%-6.81%1 Year Performance-56.31%-26.11%11.46%1.31% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics2.2313 of 5 stars$7.89+3.7%$34.80+341.1%-55.9%$461.67MN/A-2.7830Analyst ForecastNews CoverageGap DownARQTArcutis Biotherapeutics2.9332 of 5 stars$14.30-2.9%$18.80+31.5%+26.9%$1.70B$196.54M-7.99150Gap UpRXRXRecursion Pharmaceuticals2.1702 of 5 stars$4.20-0.9%$8.25+96.4%-26.4%$1.69B$58.49M-2.75400Analyst RevisionHigh Trading VolumeDNLIDenali Therapeutics4.0945 of 5 stars$11.60-1.5%$37.20+220.7%-24.3%$1.68B$330.53M-4.20430HRMYHarmony Biosciences4.5527 of 5 stars$28.40-2.9%$53.33+87.8%-2.5%$1.63B$714.73M13.46200Short Interest ↓Positive NewsGap DownBEAMBeam Therapeutics2.8409 of 5 stars$15.30+0.2%$49.45+223.2%-30.1%$1.53B$63.52M-8.69510Short Interest ↑High Trading VolumeGLPGGalapagos0.687 of 5 stars$23.04-3.0%$25.33+10.0%-15.6%$1.52B$275.65M0.001,123Upcoming EarningsNews CoverageHigh Trading VolumeCNTACentessa Pharmaceuticals2.9194 of 5 stars$11.28-3.4%$27.71+145.7%+14.1%$1.50B$6.85M-7.37200Positive NewsHigh Trading VolumeAGIOAgios Pharmaceuticals3.9392 of 5 stars$25.90+0.5%$56.57+118.4%-4.7%$1.48B$36.50M2.28390KNSAKiniksa Pharmaceuticals2.5937 of 5 stars$20.28-0.4%$37.17+83.3%+19.2%$1.47B$423.24M-144.85220Upcoming EarningsAnalyst ForecastInsider TradePositive NewsGap UpHigh Trading VolumeANIPANI Pharmaceuticals3.6214 of 5 stars$66.99-0.8%$79.75+19.0%+5.7%$1.46B$614.38M-121.80600Analyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies ARQT Alternatives RXRX Alternatives DNLI Alternatives HRMY Alternatives BEAM Alternatives GLPG Alternatives CNTA Alternatives AGIO Alternatives KNSA Alternatives ANIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEM Stock Free CGEM Stock Alerts